Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection | Zendy

Steven M. Swift | Zendy; Karen Sauve | Zendy; Cara Cassino | Zendy; Raymond Schuch | Zendy

Open Access

Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection

Author(s) -

Steven M. Swift,

Karen Sauve,

Cara Cassino,

Raymond Schuch

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02723-20

Subject(s) - daptomycin , staphylococcus aureus , microbiology and biotechnology , methicillin resistant staphylococcus aureus , antibiotics , pneumonia , in vivo , staphylococcal infections , medicine , minimum inhibitory concentration , vancomycin , biology , bacteria , genetics

Exebacase (CF-301) is a novel antistaphylococcal lysin (cell wall hydrolase) in phase 3 of clinical development for the treatment ofStaphylococcus aureus bacteremia, including right-sided endocarditis, used in addition to standard-of-care antibiotics. In the current study, the potential for exebacase to treatS. aureus pneumonia was exploredin vitro using bovine pulmonary surfactant (Survanta) andin vivo using a lethal murine pneumonia model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research